Composition for inhibiting activity of elastase and application thereof

Abstract

The invention discloses a composition for inhibiting the activity of elastinase and application of the composition, and the composition comprises 0.0001 wt%-99 wt% of elastinase. The invention provides the composition for inhibiting the activity of the elastase, the composition has the effect of inhibiting the activity of the elastase, the prepared composition can be applied to skin care cosmetics, degradation of elastin and collagen in a corium layer of skin can be reduced, skin wrinkles can be effectively prevented, and the composition has a good anti-wrinkle effect. Experimental verification proves that the method has a practical application value.

Description

Technical Field

[0001] The present application relates to the technical field of cosmetics, and in particular to a composition for inhibiting the activity of elastase and its application. Background Art

[0002] As people's living standards continue to improve and consumers' skin care concepts continue to upgrade, the demand for anti-aging products is increasing. The external characteristics of skin aging are reduced skin moisture content, dull skin tone, pigmentation, dry and rough surface, loose skin, reduced elasticity and wrinkle formation. Among them, wrinkles are the most important and obvious sign of skin aging, and also the most significant sign of aging.

[0003] Human skin tissue is divided into three parts: epidermis, dermis and subcutaneous tissue. The dermis is the supporting tissue of the skin, maintaining the firmness and elasticity of the skin. The main fibrous connective tissues in the dermis include collagen fibers, elastic fibers and reticular fibers, which are composed of collagen and elastin. The number of collagen fibers and elastic fibers decreases with the aging of the skin and disappears completely after the age of 45. Elastase is a highly selective and specific proteolytic enzyme that can degrade a variety of proteins such as collagen and elastin. Therefore, inhibiting the activity of elastase is an important way to delay skin aging.

[0004] The anti-wrinkle cosmetics in the prior art mainly achieve anti-wrinkle by promoting collagen production and promoting the proliferation of fibroblasts that can synthesize collagen and elastin, but cannot inhibit the degradation of elastin and collagen from the root. In addition, some anti-wrinkle ingredients have usage restrictions or are unstable, such as retinol, which needs to be used away from light and is irritating to the skin, and some peptide ingredients are unstable and easily decomposed and inactivated, and cannot exert their original effects. Summary of the invention

[0005] In order to solve the above problems, the present application provides a composition for inhibiting the activity of elastase, which has the effect of inhibiting elastase and can inhibit the decomposition of elastin and collagen from the root.

[0006] The present application provides a composition for inhibiting the activity of elastase, which comprises 0.0001 wt%-99 wt% of lipopeptide, preferably 0.01 wt%-5.0 wt%.

[0007] Furthermore, the lipopeptide is selected from one or more of surfactin, iturin, fenmucin, lichenin, babylonin, pamiramycin, sporemycin, mycobacterium, phospholipid inhibitor, fusarium spore killer, kurstak, bacillus, polymyxin, octapeptide and polypeptide bacteriocin.

[0008] Furthermore, the composition further comprises 0.0001 wt%-1 wt% of an amino acid composition, and the amino acid composition preferably has a content of 0.05 wt%-0.5 wt%.

[0009] Further, the amino acid composition includes one or more of glycine, proline, alanine, lysine, glutamic acid, aspartic acid, histidine, theanine, tryptophan, threonine, phenylalanine, methionine, isoleucine, leucine, and valine;

[0010] Preferably, the amino acid composition is a combination of glycine, proline, alanine and lysine;

[0011] Preferably, the mass ratio of glycine, proline, alanine and lysine is (1-4):(1-4):(1:4):(1:4).

[0012] Furthermore, the composition further comprises 0.0001 wt%-40 wt% of a polyol, preferably 0.01 wt%-10 wt%.

[0013] Furthermore, the polyol is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol and sorbitol.

[0014] Furthermore, the composition also includes one or more of water, an emollient, a humectant, a pH regulator, an emulsifier and a preservative.

[0015] Furthermore, in the composition, the content of the emollient is 0-50wt%, preferably 0.01wt%-5wt%, the content of the humectant is 0-50wt%, preferably 0.1wt%-10wt%, the content of the pH regulator is 0-50wt%, preferably 0.01wt%-1wt%, the content of the emulsifier is 0-50wt%, preferably 0.1wt%-10wt%, and the content of the preservative is 0-5wt%, preferably 0.1wt%-1wt%.

[0016] The present application provides an application of the aforementioned composition in cosmetics.

[0017] The present application also provides use of the aforementioned amino acid composition and / or polyol in promoting the effect of lipopeptide in inhibiting the activity of elastase.

[0018] Further, the amino acid composition includes one or more of glycine, proline, alanine, lysine, glutamic acid, aspartic acid, histidine, theanine, tryptophan, threonine, phenylalanine, methionine, isoleucine, leucine, and valine;

[0019] Preferably, the amino acid composition is a combination of glycine, proline, alanine and lysine;

[0020] Preferably, the mass ratio of glycine, proline, alanine and lysine is (1-4):

[0021] (1-4):(1:4):(1:4).

[0022] Furthermore, the polyol is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol and sorbitol.

[0023] The composition for inhibiting the activity of elastase described in the present application, the lipopeptide has the effect of inhibiting elastase, and can inhibit the decomposition of elastin and collagen from the root. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 These are the experimental results of the blank control group of the zebrafish anti-wrinkle experiment provided in this application.

[0025] Figure 2 These are the experimental results of the model control group of the zebrafish anti-wrinkle experiment provided in this application.

[0026] Figure 3 These are the zebrafish anti-wrinkle experimental results of Examples 3-19 provided in this application.

[0027] Figure 4 This is the VISIA facial picture of the subjects in the anti-wrinkle essence 1 group provided in this application.

[0028] Figure 5 VISIA facial images of subjects in group 1 using anti-wrinkle eye cream provided in this application. DETAILED DESCRIPTION

[0029] The following is a description of the exemplary embodiments of the present application, including various details of the embodiments of the present application to facilitate understanding, which should be considered as merely exemplary. Therefore, it should be recognized by those of ordinary skill in the art that various changes and modifications can be made to the embodiments described herein without departing from the scope and spirit of the present application. Similarly, for the sake of clarity and conciseness, the description of well-known functions and structures is omitted in the following description.

[0030] The present application provides a composition for inhibiting the activity of elastase, comprising 0.0001 wt%-99 wt% of lipopeptide, preferably 0.01 wt%-5.0 wt%.

[0031] In the composition, the content of lipopeptide can be 0.0001wt%, 0.0002wt%, 0.0005wt%, 0.001wt%, 0.005wt%, 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.4wt%, 0.6wt%, 0.8wt%, 1.0wt%, 1.5wt%, 2.0wt%, 2.5wt%, 3.0wt%, 4.0wt%, 5.0wt%, 10wt%, 15wt%, 20wt%, 30wt%, 40wt%, 50wt%, 60wt%, 70wt%, 80wt%, 90wt%, 95wt%, 99wt% and the like.

[0032] In the present application, the lipopeptide may be a cyclic or linear lipopeptide, preferably having one of the following formulae (I)-(III):

[0033]

[0034] Among them, R represents the carbon chain of the fatty acid chain, A1, A2, A3...A m They represent the 1st, 2nd, 3rd…mth amino acids on the peptide chain respectively. The carboxyl group of the fatty acid is connected to the N-terminus of A1. m The C-terminal carboxyl group is connected to the hydroxyl or amino group of other amino acids on the fatty acid or peptide chain to form a ring structure. Linear lipopeptide refers to the linear product formed after the ring opening of cyclic lipopeptide.

[0035] The lipopeptide can be various types of lipopeptides known in the art, for example, it can be from the surfactin family, the iturin family and the fenmustine (also known as fengyuansu) family; preferably, the lipopeptide is one or more selected from the following group: surfactin, iturin, fenmustine, lichenin, babylonin, pamiramycin, sporemycin, mycobacterium, phospholipid inhibitor, fusarium, kurstak, bacillus, polymyxin, octapeptide and polypeptide.

[0036] Preferably, the lipopeptide is produced by bacteria, more preferably the bacteria are wild bacteria or genetically engineered bacteria, more preferably the bacteria are selected from the group consisting of Bacillus, Pseudomonas, Streptomyces and Arthrobacter, more preferably the lipopeptide is produced by culturing Bacillus or Pseudomonas, preferably the lipopeptide synthesis-related genes are selected from the group consisting of the lipopeptide synthesis gene srfA or the fenmustine synthesis gene fen, the lichenin synthesis gene lic, the sporemycin synthesis gene The invention relates to a novel nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following: a nanostructured bacterial strain comprising the following:

[0037] In some embodiments, the lipopeptide is surfactin.

[0038] In some embodiments, the lipopeptide is iturin.

[0039] In some embodiments, the lipopeptide is phenicol.

[0040] In some embodiments, the lipopeptide is lichenin.

[0041] In some embodiments, the lipopeptide is babilin.

[0042] In some embodiments, the lipopeptide is pamirasin.

[0043] In some embodiments, the lipopeptide is a mycosporin.

[0044] In some embodiments, the lipopeptide is a mycosubtiline.

[0045] In some embodiments, the lipopeptide is phosphatidylinositol.

[0046] In some embodiments, the lipopeptide is fusaricidin.

[0047] In some embodiments, the lipopeptide is kurstak.

[0048] In some embodiments, the lipopeptide is a bacillusin.

[0049] In some embodiments, the lipopeptide is a polymyxin.

[0050] In some embodiments, the lipopeptide is octapeptidin.

[0051] In the present application, the composition also includes 0.0001wt%-1wt% of amino acid composition, amino acid is the smallest unit of protein, directly to the dermis fibroblasts play a role. It can completely penetrate epithelial cells, prevent excessive divalent metal ions from cross-linking with collagen in the skin, maintain enough collagen fibers and elastic fibers, make the skin smooth, delicate and elastic. In some embodiments, the amino acid composition content is 0.05wt%-0.5wt%. In some embodiments, the amino acid composition content is 0.05wt%-0.8wt%. For example, it can be 0.0001wt%, 0.0002wt%, 0.0005wt%, 0.001wt%, 0.005wt%, 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.4wt%, 0.6wt%, 0.8wt%, 1.0wt%, etc.

[0052] The amino acid composition comprises one or more of glycine, proline, alanine, lysine, glutamic acid, aspartic acid, histidine, theanine, tryptophan, threonine, phenylalanine, methionine, isoleucine, leucine and valine.

[0053] In some embodiments, the amino acid composition is a combination of glycine, proline, alanine and lysine. Glycine is the smallest amino acid in molecular weight, most easily absorbed and utilized by the skin, and the side bond of glycine is very small. It occupies space that other amino acids cannot occupy in collagen synthesis, and is the most important amino acid in skin collagen synthesis; proline helps to build skin collagen and can promote the growth and migration of fibroblasts; alanine participates in the reaction process of converting glucose into energy, and promotes carnosine levels, provides energy for skin cells and supports protein synthesis; lysine promotes the synthesis of growth factors and collagen, and the amino acid composition of the present application adopts a combination of glycine, proline, alanine and lysine, which not only gives full play to the effects of glycine, proline, alanine and lysine, but also glycine, proline, alanine, lysine and lipopeptides can greatly promote the inhibitory effect of lipopeptides on elastase.

[0054] In some embodiments, the mass ratio of glycine, proline, alanine, and lysine is (1-4): (1-4): (1-4): (1-4). The mass ratios of glycine, proline, alanine, and lysine should not differ too much. When the mass ratio of one amino acid is too high, it will affect the skin's absorption of the other amino acids, so that the original efficacy cannot be exerted. Only when the mass ratio of glycine, proline, alanine, and lysine is (1-4): (1-4): (1-4): (1-4), glycine, proline, alanine, and lysine are combined with lipopeptides, and the composition has the strongest inhibitory effect on elastase and better anti-wrinkle effect.

[0055] In some embodiments, the mass ratio of glycine, proline, alanine, and lysine is (3-4):(1-2):(1:2):(1:2).

[0056] In some embodiments, the mass ratio of glycine to proline is 1:(1-4).

[0057] In some embodiments, the mass ratio of glycine to proline is 1:(1-2).

[0058] In some embodiments, the mass ratio of glycine to proline is 3:(1-2).

[0059] In some embodiments, the mass ratio of glycine to proline is 3.5:(1-2).

[0060] In some embodiments, the mass ratio of glycine to proline is 4:(1-2).

[0061] Specifically, the mass ratio of glycine to proline can be 1:1, 1:2, 1:3, 1:4, 2:1, 2:2, 2:3, 2:4, 3:1, 3.2:1, 3.4:1, 3.6:1, 3.8:1, 4:1, 3:1.5, 3.2:1.5, 3.4:1.5, 3.6:1.5, 3.8:1.5, 4:1.5, 3:2, 3.2:2, 3.4:2, 3.6:2, 3.8:2, 4:2, 4:3, 4:4, etc.

[0062] In some embodiments, the mass ratio of glycine to alanine is 1:(1-4).

[0063] In some embodiments, the mass ratio of glycine to alanine is 3:(1-2).

[0064] In some embodiments, the mass ratio of glycine to alanine is 3.5:(1-2).

[0065] In some embodiments, the mass ratio of glycine to alanine is 4:(1-2).

[0066] Specifically, the mass ratio of glycine to alanine can be 1:1, 1:2, 1:3, 1:4, 2:1, 2:2, 2:3, 2:4, 3:1, 3.2:1, 3.4:1, 3.6:1, 3.8:1, 4:1, 3:1.5, 3.2:1.5, 3.4:1.5, 3.6:1.5, 3.8:1.5, 4:1.5, 3:2, 3.2:2, 3.4:2, 3.6:2, 3.8:2, 4:2, 4:3, 4:4, etc.

[0067] In some embodiments, the mass ratio of glycine to lysine is 1:(1-4).

[0068] In some embodiments, the mass ratio of glycine to lysine is 1:(1-2).

[0069] In some embodiments, the mass ratio of glycine to lysine is 3:(1-2).

[0070] In some embodiments, the mass ratio of glycine to lysine is 3.5:(1-2).

[0071] In some embodiments, the mass ratio of glycine to lysine is 4:(1-2).

[0072] Specifically, the mass ratio of glycine to lysine can be 1:1, 1:2, 1:3, 1:4, 2:1, 2:2, 2:3, 2:4, 3:1, 3.2:1, 3.4:1, 3.6:1, 3.8:1, 4:1, 3:1.5, 3.2:1.5, 3.4:1.5, 3.6:1.5, 3.8:1.5, 4:1.5, 3:2, 3.2:2, 3.4:2, 3.6:2, 3.8:2, 4:2, 4:3, 4:4, etc.

[0073] The mass ratio of proline to alanine is (1:4):(1:4).

[0074] The mass ratio of proline to alanine is (1:2):(1:2).

[0075] In some embodiments, the mass ratio of proline to alanine is 1:(1:2).

[0076] In some embodiments, the mass ratio of proline to alanine is 1.5:(1:2).

[0077] In some embodiments, the mass ratio of proline to alanine is 2:(1:2).

[0078] Specifically, the mass ratio of proline to alanine is 1:1, 1.2:1, 1.5:1, 1.6:1, 1.8:1, 2:1, 1:1.5, 1.2:1.5, 1.5:1.5, 1.6:1.5, 1.8:1.5, 2:1.5, 1:2, 1.2:2, 1.5:2, 1.6:2, 1.8:2, 2.5:1, 3:1, 3.5:1, 4:1, and the like.

[0079] The mass ratio of proline to lysine is (1:4):(1:4).

[0080] The mass ratio of proline to lysine is (1:2):(1:2).

[0081] In some embodiments, the mass ratio of proline to lysine is 1:(1:2).

[0082] In some embodiments, the mass ratio of proline to lysine is 1.5:(1:2).

[0083] In some embodiments, the mass ratio of proline to lysine is 2:(1:2).

[0084] Specifically, the mass ratio of proline to lysine is 1:1, 1.2:1, 1.5:1, 1.6:1, 1.8:1, 2:1, 1:1.5, 1.2:1.5, 1.5:1.5, 1.6:1.5, 1.8:1.5, 2:1.5, 1:2, 1.2:2, 1.5:2, 1.6:2, 1.8:2, 2.5:1, 3:1, 3.5:1, 4:1, etc.

[0085] The mass ratio of proline to alanine is (1:2):(1:2).

[0086] In some embodiments, the mass ratio of proline to alanine is 1:(1:2).

[0087] In some embodiments, the mass ratio of proline to alanine is 1.5:(1:2).

[0088] In some embodiments, the mass ratio of proline to alanine is 2:(1:2).

[0089] Specifically, the mass ratio of proline to alanine is 1:1, 1.2:1, 1.5:1, 1.6:1, 1.8:1, 2:1, 1:1.5, 1.2:1.5, 1.5:1.5, 1.6:1.5, 1.8:1.5, 2:1.5, 1:2, 1.2:2, 1.5:2, 1.6:2, 1.8:2, 2.5:1, 3:1, 3.5:1, 4:1, and the like.

[0090] The mass ratio of alanine to lysine is (1:4):(1:4).

[0091] The mass ratio of alanine to lysine is (1:2):(1:2).

[0092] In some embodiments, the mass ratio of alanine to lysine is 1:(1:2).

[0093] In some embodiments, the mass ratio of alanine to lysine is 1.5:(1:2).

[0094] In some embodiments, the mass ratio of alanine to lysine is 2:(1:2).

[0095] Specifically, the mass ratio of alanine to lysine is 1:1, 1.2:1, 1.5:1, 1.6:1, 1.8:1, 2:1, 1:1.5, 1.2:1.5, 1.5:1.5, 1.6:1.5, 1.8:1.5, 2:1.5, 1:2, 1.2:2, 1.5:2, 1.6:2, 1.8:2, 2.5:1, 3:1, 3.5:1, 4:1, etc.

[0096] In the present application, the composition further comprises 0.0001wt%-40wt% of polyol, in some embodiments the content of polyol is 0.01wt%-30wt%, in some embodiments the content of polyol is 0.01wt%-20wt%, in some embodiments the content of polyol is 0.01wt%-10wt%. For example, the content of the polyol can be 0.0001wt%, 0.0002wt%, 0.0005wt%, 0.001wt%, 0.005wt%, 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.4wt%, 0.6wt%, 0.8wt%, 1.0wt%, 1.5wt%, 2.0wt%, 2.5wt%, 3.0wt%, 4.0wt%, 5.0wt%, 10wt%, 15wt%, 20wt%, 25wt%, 30wt%, 35wt%, 40wt% and the like.

[0097] Furthermore, the polyol is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol and sorbitol.

[0098] In the composition of the present application, the lipopeptide has the effect of inhibiting elastase, and can inhibit the decomposition of elastin and collagen from the root; the amino acids in the amino acid composition are necessary components for synthesizing elastin and collagen; the polyol can change the permeability of the skin, promote the absorption of lipopeptides and amino acids, and improve the utilization rate of active ingredients. Through the synergistic cooperation of the above components, the anti-wrinkle effect is improved.

[0099] In the present application, the composition further comprises one or more of water, an emollient, a humectant, a pH adjuster, an emulsifier and a preservative.

[0100] The content of the emollient is 0-50wt%, preferably 0.01wt%-5wt%, the content of the humectant is 0-50wt%, preferably 0.1wt%-10wt%, the content of the pH adjuster is 0-50wt%, preferably 0.01wt%-1wt%, the content of the emulsifier is 0-50wt%, preferably 0.1wt%-10wt%, and the content of the preservative is 0-5wt%, preferably 0.1wt%-1wt%.

[0101] In some embodiments, the composition includes a lipopeptide and an amino acid composition.

[0102] In some embodiments, the composition includes a lipopeptide and a polyol.

[0103] In some embodiments, the composition includes a lipopeptide, an amino acid composition, and a polyol.

[0104] In some embodiments, the composition includes a lipopeptide, an amino acid composition, a polyol, and water.

[0105] In some embodiments, the composition includes a lipopeptide, an amino acid composition, a polyol, water, and a humectant.

[0106] In some embodiments, the composition consists of a lipopeptide and a polyol.

[0107] In some embodiments, the composition consists of a lipopeptide, an amino acid composition, and a polyol.

[0108] In some embodiments, the composition consists of a lipopeptide, an amino acid composition, a polyol, and water.

[0109] In some embodiments, the composition consists of a lipopeptide, an amino acid composition, a polyol, water, and a humectant.

[0110] In some embodiments, the composition consists of lipopeptide, water, emollient, humectant, pH adjuster, emulsifier and preservative.

[0111] In some embodiments, the composition consists of lipopeptide, amino acid composition, water, emollient, humectant, pH adjuster, emulsifier and preservative.

[0112] In some embodiments, the composition consists of lipopeptide, polyol, water, emollient, humectant, pH adjuster, emulsifier and preservative.

[0113] In some embodiments, the composition consists of a polyol, an amino acid composition, water, an emollient, a humectant, a pH adjuster, an emulsifier, and a preservative.

[0114] In some embodiments, the composition consists of lipopeptide, amino acid composition, polyol, water, emollient, humectant, pH adjuster, emulsifier and preservative.

[0115] When the emollient is present in the composition of the present application, the emollient includes but is not limited to fats / oils (triglycerides), fatty acid esters, ethoxylated glycerides, fatty alcohols, polydimethylsiloxanes and derivatives thereof, for example, petrolatum, mineral oil, coconut oil, sunflower seed oil, corn oil, olive oil, lanolin, capric / caprylic glycerides, dicaprylyl carbonate, isononyl isononanoate, isopropyl palmitate, PEG-6 caprylic / capric triglyceride, PEG-60 corn oil glycerol mixed esters, PEG-7 olive oil ester cetearyl alcohol, PEG-30 lanolin, cetearyl alcohol, oleyl alcohol, octyldodecanol, polydimethylsiloxane; preferably, the content of the emollient is 0.01wt%-50wt%, more preferably 0.01wt%-5wt%, for example, 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt% t%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 11wt %, 12wt%, 13wt%, 14wt%, 15wt%, 16wt%, 17wt%, 18wt%, 19wt%, 20wt%, 21wt%, 22wt%, 23wt%, 24wt% %, 25wt%, 26wt%, 27wt%, 28wt%, 29wt%, 30wt%, 31wt%, 32wt%, 33wt%, 34wt%, 35wt%, 36wt%, 37wt%, 38wt%, 39wt%, 40wt%, 41wt%, 42wt%, 43wt%, 44wt%, 45wt%, 46wt%, 47wt%, 48wt%, 49wt% or 50wt%, etc.

[0116] When the moisturizer is present in the composition of the present application, the moisturizer includes but is not limited to pseudo natural moisturizing factors, sugars, panthenol, ceramide, for example, amino acids, pyrrolidone carboxylic acid, sodium lactate, urea, hydroxyethyl urea, methyl glucose polyether, chitin derivatives, trehalose, Tremella polysaccharide, sodium hyaluronate, sugar isomers, etc. The content of the moisturizer in the composition can be 0-50wt%, preferably not more than 30%, preferably not more than 10%. For example, the content of the moisturizer can be 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 11wt%, 12wt%, 13wt%, 14wt%, 15wt%, 16wt%, 17wt%, 18wt%, 19wt%, 20wt% t%, 21wt%, 22wt%, 23wt%, 24wt%, 25wt%, 26wt%, 27wt%, 28wt%, 29wt%, 30wt%, 31wt%, 32wt%, 33wt%, 34wt%, 35wt%, 36wt%, 37wt%, 38wt%, 39wt%, 40wt%, 41wt%, 42wt%, 43wt%, 44wt%, 45wt%, 46wt%, 47wt%, 48wt%, 49wt% or 50wt%, etc.

[0117] When a pH adjuster is present in the composition of the present application, the pH adjuster includes but is not limited to citric acid, malic acid, lactic acid, arginine, caprylhydroxamic acid, triethanolamine, sodium citrate, sodium bicarbonate, sodium hydroxide, and potassium hydroxide; preferably, the content of the pH adjuster is 0.01wt%-50wt%, more preferably 0.01wt%-1wt%, for example, the pH adjuster can be 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 1.1wt%, 1.2wt%, 1.3wt%, 1.4wt%, 1.5wt%, 1.6wt%, 1.7wt%, 1.8wt%, 1.9wt%, 2w t%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 11wt%, 12wt%, 13wt%, 14wt%, 15w t%, 16wt%, 17wt%, 18wt%, 19wt%, 20wt%, 21wt%, 22wt%, 23wt%, 24wt%, 25wt%, 26wt%, 27 wt%, 28wt%, 29wt%, 30wt%, 31wt%, 32wt%, 33wt%, 34wt%, 35wt%, 36wt%, 37wt%, 38wt%, 3 9wt%, 40wt%, 41wt%, 42wt%, 43wt%, 44wt%, 45wt%, 46wt%, 47wt%, 48wt%, 49wt% or 50wt%, etc.

[0118] When an emulsifier is present in the composition of the present application, the emulsifier includes but is not limited to glyceryl stearate, glyceryl stearate citrate, sorbitan trioleate, PEG-30 dipolyhydroxystearate, polyglyceryl-10 isostearate, polyoxyethylene monostearate, lecithin, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer; preferably, the content of the emulsifier is 0.01wt%-50wt%, more preferably 0.1wt%-10wt%. For example, it may be 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 11wt%, 12wt%, 13wt%, 14wt%, 15wt%, 16wt%, 17wt%, 18wt%, 19wt% %, 20wt%, 21wt%, 22wt%, 23wt%, 24wt%, 25wt%, 26wt%, 27wt%, 28wt%, 29wt%, 30wt%, 31wt%, 32wt%, 33wt%, 34wt%, 35wt%, 36wt%, 37wt%, 38wt%, 39wt%, 40wt%, 41wt%, 42wt%, 43wt%, 44wt%, 45wt%, 46wt%, 47wt%, 48wt%, 49wt% or 50wt%, etc.

[0119] When a preservative is present in the composition of the present application, the preservative is all substances added to cosmetics for the purpose of inhibiting the growth and reproduction of microorganisms in cosmetics, including but not limited to the permitted preservatives in the "Technical Specifications for Safety of Cosmetics", and also includes other ingredients with preservative effects that are not in the above-mentioned permitted preservative list, such as methylparaben, ethylparaben, propylparaben, phenoxyethanol, sorbic acid, potassium sorbate, benzyl alcohol, 1,2-hexanediol, 1,2-pentanediol, caprylyl glycol, ethylhexylglycerin, phenoxyethanol, p-hydroxyacetophenone, raspberry ketone (p-hydroxybutyrophenone), caprylhydroxamic acid, etc.; preferably, the content of the preservative is 0.01wt%-5wt%, more preferably 0.1wt%-1wt%. For example, it may be 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 1.1wt%, 1.2wt%, 1.3wt%, 1.4wt%, 1.5wt%, 1.6wt%, 1.7wt%, 1.8wt%, 1.9wt%, 2wt%, 3wt%, 4wt%, 5wt% and the like.

[0120] The present application also provides a use of the aforementioned composition in cosmetics.

[0121] In the present application, the cosmetic dosage form may be a cream, lotion, microemulsion, gel, aqueous solution, essence, sheet mask liquid, smearable mask, spray, gel, etc.

[0122] The present application provides the use of an amino acid composition and / or a polyol in promoting the effect of lipopeptides in inhibiting the activity of elastase.

[0123] The amino acid composition comprises one or more of glycine, proline, alanine, lysine, glutamic acid, aspartic acid, histidine, theanine, tryptophan, threonine, phenylalanine, methionine, isoleucine, leucine and valine;

[0124] Preferably, the amino acid composition is a combination of glycine, proline, alanine and lysine;

[0125] Preferably, the mass ratio of glycine, proline, alanine and lysine is (1-4):

[0126] (1-4):(1:4):(1:4).

[0127] The polyol is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol and sorbitol.

[0128] Example

[0129] The experimental methods used in the following examples are all conventional methods unless otherwise specified.

[0130] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0131] Example 1 Obtaining lipopeptides

[0132] 1. Preparation of Lipopeptides

[0133] A single colony of Bacillus subtilis THY-7 / Pg3-srfA (obtained from Chinese invention patent application CN109097315A) was picked up, inoculated into LB liquid culture medium, and cultured at 37°C and 200rpm for 16 hours to obtain a seed solution, which was inoculated into a fermentation medium shake flask at a ratio of 5%. 1Mm IPTG was added when the culture was carried out at 37°C and 200rpm for 2-6 hours, and the culture was continued for 2 days to obtain a fermentation broth containing surfactin.

[0134] The fermentation medium used is composed of: 30-100 g / L of sugars, 10-50 g / L of inorganic nitrogen source, 0.5-3 g / L of organic nitrogen source, 0.1-1 g / L of KH2PO4, 0.5-0.3 g / L of Na2HPO4·12H2O, 0.002-0.01 g / L of CaCl2, 0.002-0.01 g / L of MnSO4·H2O, 0.002-0.01 g / L of FeSO4·7H2O, pH 6.5-7.5, and 0.01-20 wt% of fermentation additives (silicon defoamer, polysaccharide, amino acid or its derivatives, oligopeptide, phospholipid, glycolipid, and / or fatty acid and its derivatives).

[0135] The content of surfactant in the fermentation broth was detected by the method disclosed in the Chinese invention patent application CN105400784A. Specifically, 1 mL of fermentation broth was centrifuged at 12000 rpm for 1 minute, 100 μL of supernatant was added to 1900 μL of deionized water, mixed, filtered through a 0.22 μm filter membrane, and analyzed by HPLC. The mobile phase of HPLC analysis was methanol and water in a ratio of 85 / 15, the flow rate was 1 mL / min, the chromatographic column was a C18-ODS reverse phase column, the column temperature was 40 ° C, the UV detector, and the detection wavelength was 205 nm.

[0136] Through detection, it can be known that the content of surfactin in the fermentation broth is about 10-50g / L. Surfactant is extracted from the fermentation broth, and a powder product is obtained by freeze-drying. The content of lipopeptide in the obtained powder product is 40wt%-99.99wt%. The above powder product is purified to obtain purified lipopeptide powder, in which the lipopeptide content is 99.99wt%.

[0137] 2. Obtaining compositions containing other types of lipopeptides

[0138] Iturin, fenmucin, lichenin, babylonin, pamiramin, sporemycin, mycobacterium, phosphatidylinositol, fusarium, kurstak, bacillus, polymyxin, octapeptide and peptide bacteriocin were purchased from MedChemExpress, and are used as compositions 2 to 15 of the present application, respectively.

[0139] Table 1 Ingredients of Composition 1 to Composition 15

[0140]

[0141] Example 2 Determination of elastase inhibition rate

[0142] In this example, the inhibition rate of elastase was determined using three components, composition 1 to composition 15 of Example 1, a polyol, and an amino acid composition.

[0143] Assay method: In vitro elastase activity inhibition test

[0144] Experimental principle: Elastase reacts with the enzyme substrate Congo red-elastin and hydrolyzes it. The activity is indicated by measuring the amount of pigment entering the hydrolyzate by colorimetry. When elastase inhibitor is added to Congo red in the reaction system, the hydrolysis reaction is inhibited and the amount of pigment entering the hydrolyzate is reduced. The absorbance is measured at 495nm.

[0145] Reagents: Elastin-Congo red (purchased from Merck), porcine pancreatic elastase (10 μ / mg, purchased from Yuanye Biotechnology), boric acid (purchased from Merck), anhydrous borax (purchased from Merck)

[0146] Solvent background: 5.0 mL of pH 8.8 boric acid buffer (mix 142.8 mL of 0.05 mol / L boric acid solution with 57.2 mL of 0.05 mol / L borax solution, and add distilled water to 500 mL);

[0147] Sample group: 3.0 mL elastase solution (1 μ / mg, prepared using boric acid buffer at pH 8.8), 2.0 mL test sample solution (the test composition, polyol, and amino acid were prepared into a series of sample groups with different concentrations using boric acid buffer at pH 8.8).

[0148] Enzyme reaction group: 2.0 mL of boric acid buffer with a pH of 8.8, 3.0 mL of elastase solution;

[0149] Sample background: 2.0 mL of sample solution to be tested, 3.0 mL of boric acid buffer solution with a pH of 8.8;

[0150] Test method: Place the above reaction systems (solvent background, sample group, enzyme reaction group, sample background) in a 37°C constant temperature water bath for 60 minutes, then add 20 mg of elastin-Congo red, continue to incubate in a 37°C water bath for 10 minutes, and then measure the absorbance at 495 nm. The absorbance of the sample background is A, the absorbance of the solvent background is B, the absorbance of the sample group is C, and the absorbance of the enzyme reaction group is D. The inhibition rate calculation formula is:

[0151] 1. Inhibition rate of lipopeptide on elastase

[0152] Table 2 Inhibition rate of composition 1 to composition 15 on elastase

[0153]

[0154] When the concentration of composition 1 to composition 15 is ≥5wt%, the inhibition rate of elastase reaches 100%, so the preferred range is 0.001wt%-5wt%.

[0155] The elastase inhibitory effects of compositions 1 to 15 were compared, and IC50 (the concentration at which the inhibition rate reaches 50%) was used as the basis for evaluating the elastase inhibitory effect. The lower the IC50, the better the elastase inhibitory effect.

[0156] Table 3 IC50 and inhibition rate of elastase of composition 1 to composition 15

[0157]

[0158]

[0159] It can be seen from the data in the above table that the elastase inhibition effect is: composition 1>composition 2>composition 11>composition 3>composition 5>composition 12>composition 6>composition 7>composition 13>composition 4>composition 8>composition 9>composition 10>composition 14>composition 15; it can be seen that the elastase inhibition effect of surfactin, iturin and feninterleukin is significantly better than that of other types of lipopeptides, and the inhibition effect is: surfactin>iturin>feninterleukin.

[0160] 2. Inhibition rate of polyols on elastase

[0161] Table 4 Results of polyol inhibition of elastase

[0162]

[0163] It can be seen from the data in the table that polyols have no inhibitory effect on elastase.

[0164] 3. Inhibition rate of amino acids on elastase

[0165] Table 5 Results of amino acid inhibition rate on elastase

[0166]

[0167]

[0168] It can be seen from the data in the table that the above 16 amino acids have no inhibitory effect on elastase.

[0169] Among the three components of lipopeptide, polyol and amino acid, only lipopeptide has the effect of inhibiting elastase.

[0170] Example 3 Testing the anti-wrinkle efficacy using a zebrafish model

[0171] In this example, zebrafish were used to test the inhibition rate of the lipopeptide composition and the composition for inhibiting the activity of elastase after the lipopeptide was compounded with polyols and amino acids on the wrinkling of the zebrafish tail fin, and the anti-wrinkle effect was evaluated.

[0172] The zebrafish genome is highly homologous to the human genome, accounting for about 87%. It can reliably simulate and predict human physiology, presenting physiological characteristics similar to humans, and is recognized by the scientific community as the most sensitive in vivo method for evaluating chemicals. In addition, the structure of zebrafish skin is similar to that of human skin, including the basal layer, spinous layer, granular layer, clear layer and epidermal keratinocyte layer. The skin interstitial connective tissue, collagen and its adjacent fibroblasts and skin gene expression are similar to those of human skin. Therefore, using zebrafish to evaluate the efficacy of cosmetics has great reference value.

[0173] Experimental principle: When exposed to excessive ultraviolet rays, the collagen and elastin in the zebrafish skin are greatly reduced, which manifests as tail fin wrinkling. After adding the test substance, the change in the tail fin area of ​​the young fish after ultraviolet irradiation is measured, and the tail fin wrinkling inhibition rate is calculated to evaluate the anti-wrinkle effect of the test substance.

[0174] Reagents and materials: Wild-type AB strain zebrafish larvae, methylcellulose, zebrafish culture water, tea polyphenols.

[0175] Test method: Select 2dpf zebrafish fry with normal development under a stereo microscope and place them in a six-well cell culture plate filled with zebrafish culture water, 15 fish per well. Remove the zebrafish culture water in the six-well cell culture plate without harming the fry, and quickly add 3mL of the test solution to each well. First, mix thoroughly, cover the culture plate panel, incubate in dark for 2h, and then irradiate under ultraviolet light three times, each irradiation dose is 50J / cm 2 Each irradiation time was 15 minutes, with an interval of 30 minutes. Finally, the cells were incubated in a (28±1.0)℃ biochemical incubator in the dark for 22 hours and observed under a stereo microscope.

[0176] Experimental groups: Blank control group: containing zebrafish fry and culture water, no irradiation; model control group: containing zebrafish fry and culture water, irradiated with ultraviolet light; positive control group: containing zebrafish fry and positive control tea polyphenols, irradiated with ultraviolet light; test substance group: containing zebrafish fry and the test substance, irradiated with ultraviolet light.

[0177] Preparation of test substance: The test substance was prepared into a 10 ppm solution using zebrafish culture water.

[0178] Positive control: A 10 ppm solution of tea polyphenols was prepared using zebrafish culture water as the test substance for the positive control group.

[0179] Observation and photography: After incubation, randomly select at least 12 zebrafish from those with normal phenotypes and behaviors, fix them with 3% methylcellulose and photograph them under a stereo microscope. All zebrafish should be photographed within 2 hours using the same instrument and environment.

[0180] Image analysis: After taking the photos, the image analysis software IMAGEJ was used to analyze the zebrafish photos. The quantitative area was selected as the zebrafish tail fin, and the analysis parameter was set to area. 10 valid data of tail fin area were taken for each group.

[0181] Quantitative calculation of tail fin shrinkage inhibition rate:

[0182] Q = (A1-A2) / (A3-A2) × 100%

[0183] Where:

[0184] Q——The inhibition rate of zebrafish tail fin wrinkling in the test group compared with the model control group;

[0185] A1——the average caudal fin area of ​​zebrafish in the test group;

[0186] A2——the average tail fin area of ​​zebrafish in the model control group;

[0187] A3——the average tail fin area of ​​zebrafish in the blank control group;

[0188] The composition of each test substance and the inhibition rate of zebrafish tail fin shrinkage are as follows:

[0189] Table 6 Zebrafish anti-wrinkle experimental results

[0190]

[0191]

[0192] From the data in the above table, it can be seen that polyols and amino acids have no anti-wrinkle effect on the caudal fin of zebrafish. The anti-wrinkle rate of composition 1 after being compounded with polyols and amino acids respectively is improved, among which the butanediol and amino acid composition (glycine: proline: alanine: lysine = 3:1:1:1) has the best effect, that is, Example 3-19, the anti-wrinkle effect of zebrafish is shown in Figure 1-3 .

[0193] Example 4 Preparation of anti-wrinkle essence

[0194] In this example, the formula of the composition for inhibiting the activity of elastase in Example 3-19 is added to the cosmetic matrix to prepare a skin care essence. The ingredients and proportions of the essence matrix are as follows:

[0195] Table 7 Raw material composition and ratio of essence matrix

[0196]

[0197]

[0198] The preparation method is as follows:

[0199] Add the raw materials of phase A to the water phase reactor, add the raw materials of phase B to the oil phase reactor, start stirring and heat to 80℃-85℃ for homogenization and emulsification, add the raw materials of phase C when the temperature drops to below 45℃, stir evenly and then discharge.

[0200] Refer to Table 8 for the anti-wrinkle composition of each test essence sample.

[0201] Table 8 Anti-wrinkle composition in each test essence sample

[0202] Test sample number Anti-wrinkle composition Anti-wrinkle essence 1 Composition of Example 3-19 formulation Anti-wrinkle essence 2 Composition 2 was used to replace composition 1 in the formula of Example 3-19. Anti-wrinkle essence 3 Composition 3 was used to replace composition 1 in the formula of Example 3-19. Anti-wrinkle essence 4 Composition 4 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle essence 5 Composition 5 was used to replace composition 1 in the formula of Examples 3-19. Essence base (blank control, without anti-wrinkle composition) none

[0203] Example 5 Preparation of anti-wrinkle eye cream

[0204] In this example, the formula of the composition for inhibiting the activity of elastase in Example 3-19 is added to a cosmetic matrix to prepare an eye cream. The ingredients and proportions of the eye cream matrix are as follows:

[0205] Table 9 Raw material composition and ratio of eye cream base

[0206]

[0207]

[0208] The preparation method is as follows:

[0209] Add the raw materials of phase A to the water phase reactor, add the raw materials of phase B to the oil phase reactor, start stirring and heat to 80℃-90℃ for homogenization and emulsification, add the raw materials of phase C when the temperature drops to below 50℃, stir evenly and then discharge.

[0210] The anti-wrinkle composition in each test eye cream sample prepared is shown in Table 10.

[0211] Table 10 Anti-wrinkle composition in each test eye cream sample

[0212] Test sample number Anti-wrinkle composition Anti-wrinkle eye cream1 Composition 6 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle eye cream2 Composition 7 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle eye cream3 Composition 8 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle eye cream4 Composition 9 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle eye cream5 Composition 10 was used to replace composition 1 in the formula of Examples 3-19. Eye cream base (blank control, without anti-wrinkle composition) none

[0213] Example 6 Preparation of anti-wrinkle cream

[0214] In this example, the composition for inhibiting the activity of elastase in Example 3-19 is added to a cosmetic matrix to prepare a facial cream. The ingredients and proportions of the facial cream matrix are as follows:

[0215] Table 11 Raw material composition and ratio of cream base

[0216]

[0217]

[0218] The preparation method is as follows:

[0219] Add the raw materials of phase A to the water phase reactor, add the raw materials of phase B to the oil phase reactor, start stirring and heat to 85℃-90℃ for homogenization and emulsification, add the raw materials of phase C when the temperature drops to below 50℃, stir evenly and then discharge.

[0220] The anti-wrinkle composition in each test cream sample prepared is shown in Table 12.

[0221] Table 12 Anti-wrinkle composition in each test cream sample

[0222] Test sample number Anti-wrinkle composition Anti-wrinkle cream1 Composition 11 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle cream2 Composition 12 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle cream3 Composition 13 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle cream4 Composition 14 was used to replace composition 1 in the formula of Examples 3-19. Anti-wrinkle cream5 Composition 15 was used to replace composition 1 in the formula of Examples 3-19. Cream base (blank control, without anti-wrinkle composition) none

[0223] Example 7 Evaluation of anti-wrinkle effect

[0224] In this example, the anti-wrinkle effect of the essence, eye cream and face cream in Example 4, Example 5 and Example 6 was evaluated.

[0225] The test method is as follows:

[0226] Subject requirements: A total of 90 subjects aged 25-40 years old, regardless of gender, with no history of skin diseases and skin allergies, good health, good compliance, and able to use samples as required by staff. No cosmetics other than test samples may be used during the trial.

[0227] The subjects were randomly divided into 18 groups, each with 5 people. The samples in Example 4, Example 5 and Example 6 were used respectively. The facial wrinkles of the subjects were tested using VISIA-7. The wrinkle feature count was used to represent the wrinkle condition. The higher the feature count, the more wrinkles there were. The results are shown in Table 13 and Figure 4-Figure 5 , Figure 4 These are the VISIA facial pictures of the subjects in the anti-wrinkle essence 1 group before and after 8 weeks of use. The left side shows the VISIA facial picture before use, and the right side shows the VISIA facial picture after use. Figure 5 These are the VISIA facial pictures of the subjects in group 1 who used the anti-wrinkle eye cream before and after 8 weeks of use. The left picture is the VISIA facial picture before use, and the right picture is the VISIA facial picture after use.

[0228] Table 13 Test results of subjects

[0229]

[0230]

[0231] From the data in the table, it can be seen that the subjects who used anti-wrinkle essence 1-5 groups, anti-wrinkle eye cream 1-5 groups, and anti-wrinkle face cream 1-5 groups had less facial wrinkles after 8 weeks compared with the subjects who used the blank control samples.

[0232] Although the embodiments of the present application are described above, the present application is not limited to the above specific embodiments and application fields, and the above specific embodiments are merely illustrative and instructive, rather than restrictive. A person of ordinary skill in the art can make many forms under the guidance of this specification and without departing from the scope of protection of the claims of the present application, all of which belong to the protection of the present application.

Claims

1. A composition for inhibiting the activity of elastase, wherein: It comprises 0.0001 wt%-99 wt% of lipopeptide, preferably 0.01 wt%-5.0 wt%.

2. The composition according to claim 1, wherein The lipopeptide is selected from one or more of surfactin, iturin, fenmucin, lichenin, babylonin, pamiramycin, sporemycin, mycobacterium, phospholipid inhibitor, fusaricide, kurstak, bacillus, polymyxin, octapeptide and polypeptide.

3. The composition according to claim 1, wherein The composition further comprises 0.0001 wt%-1 wt% of an amino acid composition, and the amino acid composition preferably has a content of 0.05 wt%-0.5 wt%.

4. The composition according to claim 3, wherein The amino acid composition comprises one or more of glycine, proline, alanine, lysine, glutamic acid, aspartic acid, histidine, theanine, tryptophan, threonine, phenylalanine, methionine, isoleucine, leucine and valine; Preferably, the amino acid composition is a combination of glycine, proline, alanine and lysine; Preferably, the mass ratio of glycine, proline, alanine and lysine is (1-4):(1-4):(1:4):(1:4).

5. The composition according to claim 1, wherein The composition further comprises 0.0001 wt% to 40 wt% of a polyol, preferably 0.01 wt% to 10 wt%.

6. The composition according to claim 5, wherein The polyol is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol and sorbitol.

7. The composition according to claim 1, wherein The composition further comprises one or more of water, an emollient, a moisturizer, a pH adjuster, an emulsifier and a preservative.

8. The composition according to claim 7, wherein In the composition, the content of the emollient is 0-50wt%, preferably 0.01wt%-5wt%, the content of the humectant is 0-50wt%, preferably 0.1wt%-10wt%, the content of the pH regulator is 0-50wt%, preferably 0.01wt%-1wt%, the content of the emulsifier is 0-50wt%, preferably 0.1wt%-10wt%, and the content of the preservative is 0-5wt%, preferably 0.1wt%-1wt%.

9. Use of the composition according to any one of claims 1 to 8 in cosmetics.

10. Use of an amino acid composition and / or a polyol in promoting the effect of lipopeptides in inhibiting the activity of elastase.

11. The use according to claim 10, wherein The amino acid composition comprises one or more of glycine, proline, alanine, lysine, glutamic acid, aspartic acid, histidine, theanine, tryptophan, threonine, phenylalanine, methionine, isoleucine, leucine and valine; Preferably, the amino acid composition is a combination of glycine, proline, alanine and lysine; Preferably, the mass ratio of glycine, proline, alanine and lysine is (1-4):(1-4):(1:4):(1:4).

12. The use according to claim 10, wherein The polyol is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol and sorbitol.

Images